In the quest to develop shots against Covid-19, researchers have overcome challenges that typically make vaccine projects stretch across years if not decades. Assuming one or more of their experimental vaccines proves safe and effective in late-stage trials — a huge feat in itself — drug companies and health officials will next face a whole new set of obstacles in their effort to deliver the shots widely around the world. Preparations for vaccinating the planet’s 7.8 billion people are already underway.
Getting the Green Light
Typically, a vaccine must show that it works in trials involving thousands of volunteers before regulators consider permitting its use outside of research. While China and Russia are using special regulatory provisions to deploy Covid vaccines before they’ve undergone full testing, nine U.S. and European companies that are in the forefront of the
SARS-CoV-2, the virus that causes COVID-19, can relieve pain, according to a new study by University of Arizona Health Sciences researchers.
The finding may explain why nearly half of people who get COVID-19 experience few or no symptoms, even though they are able to spread the disease, according to the study’s corresponding author Rajesh Khanna, PhD, a professor in the College of Medicine — Tucson’s Department of Pharmacology.
“It made a lot of sense to me that perhaps the reason for the unrelenting spread of COVID-19 is that in the early stages, you’re walking around all fine as if nothing is wrong because your pain has been suppressed,” said Dr. Khanna. “You have the virus, but you don’t feel bad because you pain is gone. If we can prove that this pain relief is what is causing COVID-19 to spread further, that’s of enormous value.”
A mindfulness-based stress reduction (MBSR) course was found to benefit patients with chronic pain and depression, leading to significant improvement in participant perceptions of pain, mood and functional capacity, according to a study in the Journal of the American Osteopathic Association. Most of the study respondents (89%) reported the program helped them find ways to better cope with their pain while 11% remained neutral.
Chronic pain is a common and serious medical condition affecting an estimated 100 million people in the United States, which correlates with annual costs of approximately $635 billion. The small-scale study was conducted in a semi-rural population in Oregon where issues of affordability, addiction and access to care are common. Participants received intensive instruction in mindfulness meditation and mindful hatha yoga during an eight-week period.
“Many people have lost hope because, in most cases, chronic pain will never fully resolve,” says Cynthia Marske, DO, an
SCS EXPERT is the first expandable percutaneous lead for neuromodulation treatment for chronic pain
New investors, led by CDP Venture Capital, and including Indaco Ventures I and EUREKA! Venture, join existing participating investors in financing round
Adds to EUR 2.3M grant earlier in 2020 from the European Commission to launch SCS EXPERT
WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring, neuromodulation and brain-machine interfacing, today announced the closing of a EUR 15 million Series C financing round. New investors, led by CDP Venture Capital SGR, and including Indaco Ventures I Fund and EUREKA! Venture SGR, joined existing investors participating in this round – Principia SGR, New Frontier, Atlante Seed and Atlante Ventures (funds managed by Indaco Venture Partners SGR), High Tech Gründerfonds and F3F.
The proceeds will be partially used to accelerate the development of the Company’s second product, SCS EXPERT (EXpandable PERcu
A team of researchers in the United States and Japan reports that spinal cord stimulation (SCS) measurably decreased pain and reduced motor symptoms of Parkinson’s disease, both as a singular therapy and as a “salvage therapy” after deep brain stimulation (DBS) therapies were ineffective.
Writing in the September 28, 2020 issue of Bioelectronic Medicine, first author Krishnan Chakravarthy, MD, PhD, assistant professor of anesthesiology at University of California San Diego School of Medicine, and colleagues recruited 15 patients with Parkinson’s disease, a neurodegenerative disorder that is commonly characterized by physical symptoms, such as tremors and progressive difficulty walking and talking, and non-motor symptoms, such as pain and mental or behavioral changes.
The mean age of the patients was 74, with an average disease duration of 17 years. All of the patients were experiencing pain not alleviated by previous treatments. Eight had undergone earlier DBS, a non-invasive, pain therapy in
The MarketWatch News Department was not involved in the creation of this content.
Sep 28, 2020 (TS Newswire via Comtex) —
KD Market Insights has published a report on global Pain Therapeutics market research report. The report offers valuable market insights drivers which would aid the industry leaders to develop and line up their market strategies supported by reliable and accurate data. According to KD Market Insights report, the global Pain Therapeutics market is expected to grow at a CAGR of XX.X% during the forecast period i.e. 2020-2025. The market was held to USD XX.X Million in 2019 and is projected to reach to a valuation of USD XX.X Million in 2025. The report covers a detailed chapter on market segmentation of Pain Therapeutics market covering market segments By Drug Class, By Indication and By Distribution Channel.
The report offers an exhaustive analysis of the market trends, opportunities, growth
It’s not uncommon for people with chronic pain but no clear injury to deal with doubting physicians.
Katie Clark, a retired middle school English Language Arts teacher in Michigan with fibromyalgia, said she has been lucky with her doctors. Fibromyalgia causes chronic pain that doctors think arises from amplified pain signals in the brain and spinal cord.
“I’ve been fortunate to have doctors that mostly believe the pain I feel is real,” she said. But even then, “They don’t fully understand that it affects you emotionally, physically, your energy level, your ability to think straight. That is difficult to communicate to doctors.”
In the past, healthcare providers have ascribed to a narrow definition of pain, viewing
President and CEO of Lucid Lane. Software technology expert and digital health advocate.
About 20% of adults in the U.S. suffer from chronic pain. Unfortunately, for those millions of people, doctors and researchers are learning that painkillers — from powerful opioids to over-the-counter medications like aspirin or ibuprofen — may not actually reduce certain types of chronic pain or improve quality of life. Some painkillers, especially opioids, can also be highly addictive.
Some treatments for chronic pain begin by addressing the patient’s mental state — their beliefs about pain and the way those beliefs affect their behaviors. New technologies, including some powered by artificial intelligence, may also help make treatments for chronic pain more effective, accessible and affordable. As the president and CEO of a company that provides telehealth to people with pain and substance use issues, here are five things I believe AI and tech tools can